Stock BIIB34 BIOGEN INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Biogen Inc. Sao Paulo

Equities

BIIB34

BRBIIBBDR001

Pharmaceuticals

Market Closed - Sao Paulo
Other stock markets
 07:00:00 25/06/2024 pm IST 		5-day change 1st Jan Change
204.2 BRL +0.02% Intraday chart for Biogen Inc. +0.02% -0.47%
30/06 Japan's Eisai developing dementia drug for US market, Nikkei reports RE
28/06 Biogen, Eisai Launch Leqembi in China to Treat Alzheimer's Disease MT

Business Summary

Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:

- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;

- royalties (17,2%) ;

- other (9,1%): primarily revenues from partnership agreements.

Number of employees: 7,570

Sales per Business

USD in Million2022Weight2023Weight Delta
Innovative Therapies
100.0 %
10,173 100.0 % 9,836 100.0 % -3.32%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
55.2 %
5,532 54.4 % 5,434 55.2 % -1.77%
Europe
21.8 %
2,413 23.7 % 2,140 21.8 % -11.34%
Germany
8.8 %
926 9.1 % 868 8.8 % -6.28%
Asia
8.8 %
720 7.1 % 863 8.8 % +19.97%
Other
5.4 %
583 5.7 % 531 5.4 % -8.87%

Managers

Managers TitleAgeSince
Christopher Viehbacher CEO
 Chief Executive Officer 64 14/22/14
Michael McDonnell DFI
 Director of Finance/CFO 60 15/20/15
Nicole Murphy COO
 Chief Operating Officer - 01/15/01
Jane Grogan CTO
 Chief Tech/Sci/R&D Officer 57 02/23/02
Chuck Triano IRC
 Investor Relations Contact - 10/23/10
Michael Hencke IRO
 Public Communications Contact - 01/12/01
Michael Dambach TRE
 Treasurer 57 01/07/01
Wendell C. Taylor LAW
 General Counsel - -
Robert Kilo PRN
 Corporate Officer/Principal - -
Rachid Izzar PRN
 Corporate Officer/Principal - 01/21/01

Members of the board

Members of the board TitleAgeSince
Stephen Sherwin BRD
 Director/Board Member 75 01/10/01
William Hawkins BRD
 Director/Board Member 70 19/19/19
Caroline Dorsa CHM
 Chairman 64 03/10/03
Eric Rowinsky BRD
 Director/Board Member 67 20/10/20
Christopher Viehbacher CEO
 Chief Executive Officer 64 14/22/14
Maria Freire BRD
 Director/Board Member 69 02/21/02
Monish Patolawala BRD
 Director/Board Member 54 01/01
Jesus Mantas BRD
 Director/Board Member 55 19/19/19
Susan Langer BRD
 Director/Board Member 33 26/23/26

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 169,396,895 145,366,956 ( 85.81 %) 23,800,000 ( 14.05 %) 85.81 %

Shareholders

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
11.38 %
16,570,398 11.38 % 3 727 M R$
PRIMECAP Management Co.
11.14 %
16,220,716 11.14 % 3 649 M R$
BlackRock Advisors LLC
6.965 %
10,140,892 6.965 % 2 281 M R$
STATE STREET CORPORATION
4.634 %
6,747,008 4.634 % 1 518 M R$
T. Rowe Price Investment Management, Inc.
3.551 %
5,169,970 3.551 % 1 163 M R$
Wellington Management Co. LLP
3.517 %
5,120,142 3.517 % 1 152 M R$
JPMorgan Investment Management, Inc.
3.221 %
4,689,983 3.221 % 1 055 M R$
BlackRock Life Ltd.
2.558 %
3,724,604 2.558 % 838 M R$
Geode Capital Management LLC
2.342 %
3,409,674 2.342 % 767 M R$
Van Eck Associates Corp.
1.193 %
1,737,340 1.193 % 391 M R$
NameEquities%Valuation
BB Gestão de Recursos DTVM SA
0.000164 %
1,430 0.000164 % 46 623 R$
Bram Bradesco Asset Management S/A DTVM
0.000003 %
30 0.000003 % 978 R$

Holdings

NameEquities%Valuation
DENALI THERAPEUTICS INC.
8.94%
 12,751,365 8.94% 236,665,334 $
SAGE THERAPEUTICS, INC.
10.37%
 6,241,473 10.37% 69,342,765 $
SANGAMO THERAPEUTICS, INC.
7.06%
 14,652,466 7.06% 8,263,991 $

Company contact information

Biogen, Inc.

225 Binney Street

02142, Cambridge

+617 679 2000

http://www.biogen.com
address Biogen Inc.(BIIB34)

Group companies

NameCategory and Sector
Biogen MA, Inc.
Logo Biogen MA, Inc.

Biogen MA, Inc.

BiotechnologyHealth Technology

Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA.

Biotechnology
Biogen International GmbH
Logo Biogen International GmbH

Biogen International GmbH

Pharmaceuticals: MajorHealth Technology

Biogen International GmbH produces pharmaceuticals. It develops medicines for psoriasis and multiple sclerosis. Its products include FUMADERM and BG-12. The company was founded in 1983 and is headquartered in Lucerne, Switzerland.

Pharmaceuticals: Major

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per region

Ratings for Biogen Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
35
Last Close Price
231.8 USD
Average target price
283.2 USD
Spread / Average Target
+22.14%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CSL LIMITED Stock CSL Limited
+2.08% 9.52TCr
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
-4.34% 3.75TCr
UCB Stock UCB
+76.49% 2.82TCr
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-14.61% 1.56TCr
INCYTE CORPORATION Stock Incyte Corporation
-3.46% 1.36TCr
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-12.31% 1.15TCr
ALTEOGEN INC. Stock ALTEOGEN Inc.
+184.77% 1.08TCr
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-54.13% 923.34Cr
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.69% 909.4Cr
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. BIIB Stock
  4. BIIB34 Stock
  5. Company Biogen Inc.